Springfield, VA, June 27, 2014 --(PR.com
)-- The capacity of pharmaceutical contract manufacturing organizations (CMOs) to produce cytotoxic injectable drugs during the next five years will be tight, according to a new in-depth special report from PharmSource.
The report, The Demand and Supply for Contract Manufacturing of Cytotoxic Injectable Drugs Through 2019, presents detailed research and insight into the CMO industry’s ability to meet projected demand.
In developing the report, PharmSource’s expert researchers thoroughly investigated quantitative factors such as FDA submissions and approvals, CMO closures and expansions, and injectable drugs currently in pipeline, including antibody drug conjugates (ADCs).
PharmSource researchers found that as an industry, CMOs have lost considerable capacity to manufacture cytotoxic injectable drugs. Indeed, although 21 CMOs claim they can produce cytotoxic injectable drugs, only five actually have the capability, track record and market focus to be considered seriously for manufacturing high-value products like ADCs, said Jim Miller, president of PharmSource.
Given the current environment, PharmSource researchers concluded that CMOs should be able to maintain pricing power and perhaps even force drug sponsors to commit to projects sooner than they’d like to in order to ensure necessary space, he said.
“The information we uncover in our latest report should prompt bio/pharmaceutical companies to reconsider their sourcing strategies and assess the adequacy of the CMO industry to manufacture products in pipeline,” he said. “It also should help CMOs make strategic investment decisions when it comes to producing cytotoxic injectable drugs.”
The 34-page PharmSource report complements its recent analysis of conventional injectable drug manufacturing capacity, The Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2019. The report and supplement are considered required reading for CMO executives, bio/pharmaceutical sourcing and procurement executives, and private equity investors.
To learn more about the report, contact PharmSource at www.pharmsource.com or 1.703.383.4903.
PharmSource is the recognized authority of unbiased knowledge about the global bio/pharmaceutical contract services industry. The company’s publications, databases, research tools and analyses inform buyers and sellers of bio/pharma contract services about industry trends, activities and partnership opportunities. Since 1996, CMOs, CDMOs and CROs worldwide have looked to PharmSource for critical information delivered with timeliness and integrity.